A consortium of VC firms and specialist investors have backed a $58m series-E funding round for cancer immunotherapy developer Immatics.
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap